Lanthanum carbonate - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for lanthanum carbonate and what is the scope of patent protection?

Lanthanum carbonate is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa, Barr, Invagen Pharms, and Natco Pharma Ltd, and is included in five NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lanthanum carbonate has ninety-one patent family members in thirty-one countries.

There are nine drug master file entries for lanthanum carbonate. Six suppliers are listed for this compound.

Summary for lanthanum carbonate

International Patents:	91
US Patents:	4
Tradenames:	2
Applicants:	4
NDAs:	5
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	36
Clinical Trials:	43
Patent Applications:	1,525
Drug Prices:	Drug price trends for lanthanum carbonate
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lanthanum carbonate
What excipients (inactive ingredients) are in lanthanum carbonate?	lanthanum carbonate excipients list
DailyMed Link:	lanthanum carbonate at DailyMed

See drug prices for lanthanum carbonate

Recent Clinical Trials for lanthanum carbonate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University of Lodz	Phase 4
Medical Universtity of Lodz	Phase 4
Universitair Ziekenhuis Brussel	Phase 3

See all lanthanum carbonate clinical trials

Pharmacology for lanthanum carbonate

Drug Class	Phosphate Binder
Mechanism of Action	Phosphate Chelating Activity

Anatomical Therapeutic Chemical (ATC) Classes for lanthanum carbonate

V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for LANTHANUM CARBONATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FOSRENOL	Oral Powder	lanthanum carbonate	750 mg and 1000 mg	204734	1	2015-11-25
FOSRENOL	Chewable Tablet	lanthanum carbonate	500 mg, 750 mg and 1000 mg	021468	3	2008-10-27

US Patents and Regulatory Information for lanthanum carbonate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-004	Nov 23, 2005	AB	RX	Yes	Yes	7,465,465	⤷ Subscribe	Y			⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-001	Oct 26, 2004		DISCN	No	No	7,381,428	⤷ Subscribe				⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-004	Nov 23, 2005	AB	RX	Yes	Yes	7,381,428	⤷ Subscribe				⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-001	Sep 24, 2014		RX	Yes	No	8,980,327	⤷ Subscribe	Y			⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-001	Oct 26, 2004		DISCN	No	No	7,465,465	⤷ Subscribe	Y			⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-001	Sep 24, 2014		RX	Yes	No	7,465,465	⤷ Subscribe	Y			⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for lanthanum carbonate

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-001	Oct 26, 2004	5,968,976	⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-001	Sep 24, 2014	5,968,976	⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-001	Oct 26, 2004	7,465,465	⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-004	Nov 23, 2005	7,465,465	⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-003	Nov 23, 2005	7,465,465	⤷ Subscribe
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-002	Sep 24, 2014	5,968,976	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for lanthanum carbonate

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
Brazil	PI0413394	formulação de lantánio mastigável em tablete, formulação farmacêutica em tablete ou em pó, método para tratar hiperfosfatemia, uso de uma quantidade terapeuticamente efetiva de uma formulação de um composto de lantánio, processo para preparar uma formulação em tablete de um composto de lantánio	⤷ Subscribe
Australia	2009202429	Pharmaceutical formulation comprising lanthanum compounds	⤷ Subscribe
Hungary	E024906		⤷ Subscribe
Australia	2006313490	Stabilized lanthanum carbonate compositions	⤷ Subscribe
European Patent Office	1785141	Compositions stabilisée de lanthane carbonate (Stabilized lanthanum carbonate compositions)	⤷ Subscribe
South Korea	20080071170	STABILIZED LANTHANUM CARBONATE COMPOSITIONS	⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.